Cytek Biosciences, Inc. (CTKB) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
CTKB EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CTKB Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 51.8% | -20.0% | -33.0% |
| 2024 | 55.4% | -10.2% | -3.0% |
| 2023 | 56.7% | -14.4% | -6.3% |
| 2022 | 61.6% | -1.1% | 1.6% |
| 2021 | 61.9% | 7.2% | 2.3% |
Download Data
Export CTKB earnings history in CSV or JSON format
Free sign-in required to download data
Cytek Biosciences, Inc. (CTKB) Earnings Overview
As of May 9, 2026, Cytek Biosciences, Inc. (CTKB) reported trailing twelve-month net income of -$74M, reflecting -1028.0% year-over-year growth. The company earned $-0.57 per diluted share over the past four quarters, with a net profit margin of -33.0%.
Looking at the long-term picture, CTKB's historical earnings data spans multiple years. The company achieved its highest annual net income of $19M in fiscal 2020.
Cytek Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ILMN ($853M net income, 19.6% margin), HOLX ($544M net income, 13.8% margin), AZTA (-$178M net income, -9.4% margin), CTKB has room to improve margins relative to the peer group. Compare CTKB vs ILMN →
CTKB Earnings vs Peers
Earnings metrics vs comparable public companies
CTKB Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$67M | -1005.3% | -$40M | $-0.52 | -33.0% | -20.0% |
| 2024 | -$6M | +50.4% | -$21M | $-0.05 | -3.0% | -10.2% |
| 2023 | -$12M | -571.6% | -$28M | $-0.09 | -6.3% | -14.4% |
| 2022 | $3M | -14.2% | -$2M | $0.02 | 1.6% | -1.1% |
| 2021 | $3M | -84.5% | $9M | $0.03 | 2.3% | 7.2% |
| 2020 | $19M | +215.4% | $14M | $0.02 | 20.9% | 14.7% |
| 2019 | -$17M | - | -$17M | $-0.13 | -29.1% | -29.8% |
See CTKB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CTKB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CTKB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCTKB — Frequently Asked Questions
Quick answers to the most common questions about buying CTKB stock.
Is CTKB growing earnings?
CTKB EPS fell to $-0.57, with earnings declining -1028.0%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-74M.
What are CTKB's profit margins?
Cytek Biosciences, Inc. net margin is -33.0%, with operating margin at -20.0%. Below-average margins reflect competitive or cost pressures.
How consistent are CTKB's earnings?
CTKB earnings data spans 2019-2025. The declining earnings trend is -1028.0% YoY. Historical data enables comparison across business cycles.